Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: A systematic review and meta-analysis

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Chant, Clarence ^a,b   Leung, Ann ^a   Friedrich, Jan O ^b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

DRUG ADMINISTRATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; META ANALYSIS; MORTALITY; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; DRUG ADMINISTRATION SCHEDULE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; LENGTH OF STAY; TREATMENT FAILURE;

EID: 84888221469     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13134     Document Type: Article

References (95)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12. 10.1086/595011, 19035777.
2. Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2012, 2:37-53. 10.1186/2110-5820-2-37, 3475088, 22898246.
3. Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011, 27:1-18. 10.1016/j.ccc.2010.11.003, 21144983.
4. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin: DICP. Ann Pharmacother 1991, 25:1050-1057.
5. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med 2009, 37:2071-2078. 10.1097/CCM.0b013e3181a0054d, 19384201.
6. Kasiakou SK, Sermaides G, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:581-589. 10.1016/S1473-3099(05)70218-8, 16122681.
7. Falagas ME, Tansarli GS, Ikawa, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013, 56:272-282. 10.1093/cid/cis857, 23074314.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
10. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13. 10.1186/1471-2288-5-13, 1097734, 15840177.
11. The Cochrane Handbook Available at http://handbook.cochrane.org/ Home > Part 2: General methods for Cochrane reviews > 7 Selecting studies and collecting data > 7.7 Extracting study results and converting to the desired format> 7.7.3 Data extraction for continuous outcomes > 7.7.3.5 Medians and interquartile ranges.
12. Georges B, Archambaud M, Saivin S, Decun JF, Cougot P, Mazerolles M, Andrieu P, Suc CH, Houin G, Chabanon G, Verenque CH. Continuous versus intermittent cefepime infusion in critical care patients: preliminary findings. Pathol Biol 1999, 47:483-485.
13. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000, 179:436-440. 10.1016/S0002-9610(00)00388-3, 11004326.
14. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001, 17:497-504. 10.1016/S0924-8579(01)00329-6, 11397621.
15. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit J-F, Similowski T, Mentec H, Mier L, Dreyfuss D. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467. 10.1128/AAC.45.9.2460-2467.2001, 90678, 11502515.
16. Buijk SLCE, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudates during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49:121-128. 10.1093/jac/49.1.121, 11751775.
17. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005, 43:360-369. 10.5414/CPP43360, 16119511.
18. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006, 28:122-127. 10.1016/j.ijantimicag.2006.02.020, 16815689.
19. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007, 59:285-291.
20. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51:3304-3310. 10.1128/AAC.01318-06, 2043189, 17620371.
21. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008, 31:122-129. 10.1016/j.ijantimicag.2007.09.009, 18055183.
22. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012, 16:R113. 10.1186/cc11405, 3580671, 22742765.
23. Schentag JJ, Smith IL, Swanson DJ. Role for dual individualization with cefmenoxime. Am J Med 1984, 77:43-50.
24. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006, 40:219-223. 10.1345/aph.1G467, 16449546.
25. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363. 10.1086/510590, 17205441.
26. Lorente L, Jimenez A, Palemero S, Jimenez JJ, Iribarren JL, Santana M, Martin MM, Mora ML. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007, 29:2433-2439. 10.1016/j.clinthera.2007.11.003, 18158083.
27. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25:69-77. 10.1016/j.jcrc.2009.02.014, 19427167.
28. Yost RJ, Cappelletty DM, RECEIPT Study group RECEIPT Study group: The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 2011, 31:767-775. 10.1592/phco.31.8.767, 21923603, RECEIPT Study group.
29. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013, 56:236-244. 10.1093/cid/cis856, 23074313.
30. Dow RJ, Rose WE, Fox BC, Thorpe JM, Fish JT. Retrospective study of prolonged versus intermittent infusion piperacilin-tazobactam and meropenem in intensive care unit patients at an academic medical center. Infect Dis Clin Pract 2011, 19:413-417.
31. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009, 33:464-468. 10.1016/j.ijantimicag.2008.10.025, 19150225.
32. Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009, 33:287-294. 10.1016/j.ijantimicag.2008.07.018, 18805676.
33. Itabashi S. Clinical efficacy of prolonged (4 hour) drip infusion of meropeneme against severe pneumonia. Japan J Antibiotics 2007, 170:60-63.
34. Akers KS, Cota JM, Chung KK, Renz EM, Mende K, Murray CK. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal impairment therapy. J Burn Care Res 2012, 33:e254-e262. 10.1097/BCR.0b013e31825042fa, 22878490.
35. Lee GC, Liou H, Yee R, Quan CF, Neldner K. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 2012, 24:2297-2300.
36. Arnold HM, Hollands JM, Skrupky LP, Smith JR, Juang PH, Hampton NB, McCormick S, Reichley RM, Hoban A, Hoffman J, Micek ST, Kollef MH. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Ann Pharmacother 2013, 47:170-180. 10.1345/aph.1R523, 23341160.
37. Hsaiky L, Murray KP, Kokoska L, Desai N, Cha R. Standard versus prolonged doripenem infusion for treatment of gram-negative infections. Ann Pharmacother 2013, 47:999-1006. 10.1345/aph.1S032, 23821611.
38. Chapuis TM, Giannoni E, Majcherczyk PA, Chiolero R, Schaller MD, Berger MM, Bolay S, Decosterd LA, Burnon D, Moreillon P. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51. 10.1186/cc8941, 2887166, 20359352.
39. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339. 10.1016/j.ijantimicag.2010.06.008, 20685085.
40. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration?. Crit Care Med 2009, 37:926-933. 10.1097/CCM.0b013e3181968e44, 19237898.
41. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008, 30:674-681. 10.1097/FTD.0b013e31818b6b2f, 19057371.
42. Del Mar Fernandez De Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007, 33:279-285. 10.1007/s00134-006-0470-5, 17165021.
43. Fish DN. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in medical Intensive Care Unit. Int J Antimicrob Agents 2007, 29:715-723. 10.1016/j.ijantimicag.2007.02.006, 17433631.
44. Roos JF, Lipman J, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007, 33:781-788. 10.1007/s00134-007-0573-7, 17342515.
45. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006, 58:987-993. 10.1093/jac/dkl349, 16943209.
46. Boselli E, Breilh D, Rimmele T, Djabarouti S, Saux M-C, Chassard D, Allaouchiche B. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 2005, 33:104-109. 10.1097/01.CCM.0000150265.42067.4C, 15644655.
47. Navarro AS, Gandarillas C-IC, Lerma FA, Menacho YA, Dominguez-Gil A. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokinet 2005, 44:627-635. 10.2165/00003088-200544060-00004, 15910010.
48. Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003, 29:1528-1534. 10.1007/s00134-003-1859-z, 12856119.
49. Pea F, Di QE, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003, 42:589-598. 10.2165/00003088-200342060-00008, 12793843.
50. Benko R, Matuz M, Doro P, Peto Z, Molnar A, Hajdu E, Nagy E, Gardi J, Soos G. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. Int J Antimicrob Agents 2007, 30:162-168. 10.1016/j.ijantimicag.2007.03.016, 17570646.
51. Pea F, Poz D, Viale P, Pavan F, Furlanut M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 2006, 58:380-386. 10.1093/jac/dkl226, 16735422.
52. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49:1337-1339. 10.1128/AAC.49.4.1337-1339.2005, 1068632, 15793108.
53. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002, 19:105-110. 10.1016/S0924-8579(01)00474-5, 11850162.
54. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999, 43:309-311. 10.1093/jac/43.2.309, 11252342.
55. Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999, 43:523-527. 10.1093/jac/43.4.523, 10350382.
56. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996, 40:691-695. 163181, 8851594.
57. Nicolau DP, McNabb J, Lacy MK, Li J, Quintiliani R, Nightingale CH. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clin Drug Invest 1999, 18:133-139.
58. Nicolau DP, Lacy MK, McNabb J, Quintiliani R, Nightingale CH. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Pract 1999, 8:45-49.
59. Duszynska W, Taccone FS, Switala M, Hurkacz M, Kowalska-Krochmal B, Kubler A. Continuous infusion of piperacillin/ tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs. Int J Antimicrob Agents 2012, 39:153-158. 10.1016/j.ijantimicag.2011.10.011, 22154855.
60. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005, 49:2421-2428. 10.1128/AAC.49.6.2421-2428.2005, 1140495, 15917542.
61. Suyama H, Ikawa K, Morikawa N, Ikeda K, Fujiue Y, Morikawa S, Kaneko K, Kuwabara M, Yamanoue T. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. Japan J Antibiotics 2008, 61:303-313.
62. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35:156-163. 10.1016/j.ijantimicag.2009.10.008, 20018492.
63. Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011, 39:19-25. 10.1097/CCM.0b013e3181fa36fb, 20890189.
64. Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G. Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia [French]. Pathol Biol 2005, 53:546-550. 10.1016/j.patbio.2005.06.002, 16023303.
65. Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, Moore CL, Patel S, Allen M, Peterson E, Wiemken T, Cano E, Mangino JE, Kett DH, Ramirez JA, Zervos MJ. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138:1356-1362. 10.1378/chest.09-2453, 20558550.
66. Lorenzen JM, Broll M, Kaever V, Burhenne H, Hafer C, Clajus C, Knitsch W, Burkhardt O, Kielstein JT. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012, 7:385-390. 10.2215/CJN.05690611, 3302675, 22223613.
67. Ocampos-Martinez E, Penaccini L, Scolletta S, Abdelhadii A, Devigili A, Cianferoni S, de Backer D, Jacobs F, Cotton F, Vincent JL, Taccone FS. Determinant of early inadequate vancomycin concentrations during continuous infusion in septic patients. Int J Antimicrob Agents 2012, 39:332-337. 10.1016/j.ijantimicag.2011.12.008, 22333933.
68. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimization. Int J Antimicrob Agents 2012, 39:420-423. 10.1016/j.ijantimicag.2011.12.011, 22386742.
69. Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother 2012, 67:1207-1210. 10.1093/jac/dks022, 22351682.
70. Cade JF, Presneill J, Sinickas V, Hellyar A. The optimal dosage of ceftazidime for severe lower respiratory tract infections. J Antimicrob Chemother 1993, 32:611-622. 10.1093/jac/32.4.611, 8288503.
71. Cade JF, Presneill J, Keighley C, Sinickas V. Efficacy of a low dose of cefotaxime in serious chest infections. Chest 1992, 101:1393-1398. 10.1378/chest.101.5.1393, 1582303.
72. Schwigon CD, Hulla FW, Schulze B, Maslak A. Timentin in the treatment of nosocomial bronchopulmonary infections in intensive care units. J Antimicrob Chemother 1986, 17:115-122.
73. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008, 23:422-430. 10.1016/j.jcrc.2007.11.011, 18725050.
74. Arzuaga A, Maynar J, Gascón AR, Isla A, Corral E, Fonseca F, Sánchez-Izquierdo JA, Rello J, Canut A, Pedraz JL. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005, 45:168-176. 10.1177/0091270004269796, 15647409.
75. Eagye KJ, Kuti JL, Sutherland CA, Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US Hospitals. Clin Ther 2009, 31:2678-2688. 10.1016/j.clinthera.2009.11.021, 20110010.
76. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005, 27:762-772. 10.1016/j.clinthera.2005.06.013, 16117983.
77. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapeutics 2003, 23:291-295.
78. Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994, 28:863-868.
79. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011, 66:343-349. 10.1093/jac/dkq348, 20926397.
80. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150. 10.1093/jac/dkp139, 19398460.
81. Revilla N, Martin-Suarez A, Perez MP, Gonzalez FM, Fernandez de Gatta Mdel M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol 2010, 70:201-212. 10.1111/j.1365-2125.2010.03679.x, 2911550, 20653673.
82. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapeutics 2010, 30:453-462.
83. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapeutics 2001, 21:549-555.
84. Moriyama B, Henning SA, Neuhauser MM, Danner RL, Walsh TJ. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother 2009, 43:1324-1337. 10.1345/aph.1L638, 19584386.
85. Mah GT, Mabasa VH, Chow I, Ensom MHH. Evaluation outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review. Ann Pharmacother 2012, 46:265-275. 10.1345/aph.1Q378, 22274145.
86. Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D. A simplified acute physiology score for ICU patients. Crit Care Med 1984, 12:975-977. 10.1097/00003246-198411000-00012, 6499483.
87. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758. 10.1001/jama.286.14.1754, 11594901.
88. Knaus WA, Draper EA, Wagner DP, Zimmermann JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
89. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. Erratum, JAMA 1994, 271:1321, 10.1001/jama.1993.03510240069035, 8254858.
90. Mackinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefipime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351. 10.1016/j.ijantimicag.2007.12.009, 18313273.
91. Roberts DM, Roberts JA, Roberts MS, Liu Z, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012, 40:1523-1528. 10.1097/CCM.0b013e318241e553, 22511133, RENAL Replacement Therapy Study Investigators.
92. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutc initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012, 142:30-39. 10.1378/chest.11-1671, 22194591.
93. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med 2009, 151:264-269. 10.7326/0003-4819-151-4-200908180-00135, 19622511, PRISMA Group.
94. Hróbjartsson A, Thomsen AS, Emanuelson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and non-blinded assessors. CMAJ 2012, 185:E201-E211.
95. Kollef M, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R. A randomized trial of 7-day doripenem versus 10 day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012, 16:R218. 10.1186/cc11862, 3672596, 23148736.